You just read:

Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with Advanced HER2-Overexpressing or HER2-Mutated Non-Squamous Non-Small Cell Lung Cancer

News provided by

Daiichi Sankyo Company, Limited

31 May, 2018, 13:00 BST